A phase 2b trial of PH80 for the treatment of premenstrual dysphoric disorder (PMDD)
Latest Information Update: 16 Feb 2024
At a glance
- Drugs PH 80 (Primary)
- Indications Premenstrual dysphoric disorder
- Focus Therapeutic Use
- 16 Feb 2024 New trial record
- 13 Feb 2024 According to a Vistagen Therapeutics media release, upon successful exploratory Phase 2A trials of PH80 in two women's health indications, preparations and planning are underway for U.S Phase 2B development of hormone-free PH80 for the treatment of vasomotor symptoms (hot flashes) due to menopause and, potentially, premenstrual dysphoric disorder (PMDD).